Intra-arterial Mannitol
Phase 2Small molecule
Intra-arterial Mannitol is one of 98 small molecule programs targeting Relapsed/Refractory. It is currently in Phase 2.
2
Indications
3
Total Trials
2
Active Trials
97
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
160 competitors in Glioblastoma
#DrugCompanyPhaseTrials
1Avastin
RochePhase 3
Keytruda
Merck & Co.Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Yervoy
Bristol-Myers SquibbPhase 3
Ceenu
AAzurity Pharmaceuticals
Phase 3
Antabuse
TevaPhase 3
Zejula
GGlaxo Dba Glaxosmithkline
Phase 3
Feraheme
AAzurity Pharmaceuticals
Phase 3
Sprycel
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Cancer1 trial
Relapsed/Refractory1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Intra-arterial Mannitol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- NNorthwell Health